Please login to the form below
Alnylam Pharmaceuticals
This page shows the latest Alnylam Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for treating a hereditary form of amyloidosis, the RNA interference (RNAi) ... for standard of care
Latest news
-
Alnylam’s RNAi therapeutic expanded by FDA in advanced primary hyperoxaluria type 1
Alnylam Pharmaceuticals’ label expansion for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, has been approved by the US Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria ... PH1. Jorge
-
Alnylam discovers mutations in stomach fat gene that could protect against abdominal obesity
Alnylam Pharmaceuticals and its collaborators have identified mutations in the INHBE gene associated with protection against abdominal obesity and metabolic syndrome, a condition affecting more than 20% of adults worldwide, the ... Cardiometabolic
-
TMC’s full data for inclisiran impresses at ESC
TMC licensed the rights to inclisiran from Alnylam Pharmaceuticals, and the drug still uses Alnylam’s delivery platform.
-
Fishawack acquires Dudnyk
Dudnyk specialises in insight-driven brand solutions for speciality physicians and their patients, and has worked on briefs for Shire, Alnylam and Jazz Pharmaceuticals.
-
RNA interference rebirth
Nevertheless, the negative perception was probably boosted by the fact that the announcement came shortly after Novartis decided not to take a $100m licence with RNAi specialist Alnylam Pharmaceuticals. ... or so," stated Akshay Vaishnaw, senior vice
RNA interference rebirth
More from news
Approximately 3 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Managing value: Why early asset development and commercialisation are important
For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Editas Medicine adds to board of directors
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... Alnylam Pharmaceuticals.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Managing value: Why early asset development and commercialization is important
For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- An EU emergency health fund to limit the impact of future crises
- A rough guide to... advisory boards
PMHub
The Creative Engagement Group
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
